NUCB2: A novel DNA binding protein with potential as a drug target or biomarker

Target Name: NUCB2

NCBI ID: G4925

NUCB2

NUCB2: A novel DNA binding protein with potential as a drug target or biomarker

NUCB2 (Nucleotide-binding protein subfamily B subfamily 2) is a protein that plays a crucial role in various cellular processes, including DNA replication, transcription, and repair. NUCB2 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-related NUCB2 mutations

NUCB2 mutations have been identified in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. These mutations can alter NUCB2's stability, function, or interactions with other proteins, leading to disruptions in cellular processes that contribute to the development and progression of these diseases.

For example, NUCB2 mutations have been implicated in the development of breast cancer, where increased NUCB2 activity has been associated with poor prognosis. Similarly, NUCB2 mutations have also been identified in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and have been linked to the progression of these conditions.

Drug targeting NUCB2

NUCB2 has been identified as a potential drug target due to its unique structure and its ability to interact with various molecules, including DNA, RNA, and protein. Researchers have designed drugs that specifically target NUCB2 and have shown promising results in preclinical studies. These drugs have been shown to induce apoptosis (programmed cell death) in NUCB2-mutated cells, which can be a potential mechanism for their efficacy in treating cancer and other diseases.

Biomarker potential

NUCB2 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. NUCB2's expression and function have been shown to be altered in these conditions, and researchers have used NUCB2 as a biomarker to monitor disease progression and assess the efficacy of treatments.

For example, researchers have used NUCB2 levels as a biomarker to assess the efficacy of chemotherapy in breast cancer. They found that NUCB2 levels were significantly elevated in breast cancer cells compared to normal cells, and that treatment with chemotherapy led to a significant decrease in NUCB2 levels. This suggests that NUCB2 levels can be a sensitive biomarker for monitoring the effectiveness of cancer treatments.

Conclusion

In conclusion, NUCB2 is a protein that has the potential to be a drug target or biomarker for various diseases. Its unique structure and ability to interact with various molecules make it an attractive target for drug development, and its role in various cellular processes makes it a potential biomarker for disease progression. Further research is needed to fully understand the implications of NUCB2 mutations in disease and to develop effective treatments for these conditions.

Protein Name: Nucleobindin 2

Functions: Calcium-binding protein which may have a role in calcium homeostasis (By similarity). Acts as a non-receptor guanine nucleotide exchange factor which binds to and activates guanine nucleotide-binding protein (G-protein) alpha subunit GNAI3 (By similarity)

The "NUCB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUCB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets